{'fraction_non_alphanumeric': 0.021702838063439065, 'fraction_numerical': 0.01335559265442404, 'mean_word_length': 5.122448979591836, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Role of alkaline phosphatase Regan isoenzyme in prognosis of patients with osteosarcoma].

The presence of Regan isoenzyme (the heat stable fraction of alkaline phosphatase) in serum of patients with osteosarcoma has been proposed as a prognostic factor indicating the metastatic evolution of the disease. This work reports on 9 patients with osteosarcoma. In 4 of them Regan isoenzyme was present 4, 6, 12, and 16 months before clinical-instrumental evidence of lung metastases. These results further support the significance of this isoenzyme as a marker of relapse in an early subclinical stage.